首页> 外文OA文献 >Effect of Prophylactic Intravesical Instillation of Pirarubicin to Prevent Recurrent Bladder Tumors Following Nephroureterectomy for Upper Urinary Tract Cancer
【2h】

Effect of Prophylactic Intravesical Instillation of Pirarubicin to Prevent Recurrent Bladder Tumors Following Nephroureterectomy for Upper Urinary Tract Cancer

机译:预防性膀胱灌注吡柔比星预防上尿路癌肾切除术后膀胱肿瘤复发的效果

摘要

We retrospectively evaluated 23 patients who had been administered pirarubicin by intravesical instillation once weekly for 5 weeks, after undergoing surgery for upper urinary tract cancer between May 2003 and October 2008. We compared their clinical records with those of 19 patients with upper urinary tract cancer subjected to nephroureterectomy between 1998 and 2008, and who did not receive intravesical instillation of pirarubicin. This prophylactic therapy was well tolerated and contributed to reduce the rate of bladder recurrence. The non-recurrence rate at 2 years was 87.0% in the instillation group and 68.4% in the non-instillation group (P=0.0025). The overall analysis of the study population did not reveal any statistically significant risk factors of bladder recurrence.
机译:我们回顾性评估了23例在2003年5月至2008年10月之间接受上尿路癌手术后每周一次通过膀胱内滴注吡柔比星治疗的患者,共5周。我们将他们的临床记录与19例接受上尿路癌治疗的患者进行了比较于1998年至2008年间接受肾盂切除术,并且未接受吡柔比星膀胱内滴注。这种预防性治疗耐受性良好,有助于降低膀胱复发率。滴注组2年的无复发率为87.0%,不滴注组为68.4%(P = 0.0025)。对研究人群的总体分析未发现任何统计学上显着的膀胱复发危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号